Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Aleris acquires Proxima

Aleris, an operating subsidiary to Investor, has reached an agreement to acquire Swedish healthcare provider Proxima Intressenter AB for an enterprise value of SEK 1,080 m. The acquisition will be financed by Investor and external debt. Investor will provide approximately SEK 750 m. in equity. For 2011, Proxima’s annual revenue is estimated at SEK 1.0 bn. and EBITDA at approximately SEK 95 m. Synergies generated by the combination of the two companies are estimated at a total SEK 30 m., of which approximately SEK 20 m. with full effect by the end of 2012. “The acquisition of Proxima

IAR Systems Launched as a Listed Company

Yesterday, Annual General Meeting in Intoi AB decided to change the company's name to IAR System Group AB.  Thereby, IAR Systems is launched as a listed company on NASDAQ OMX, Stockholm. IAR Systems is the world's leading provider of software for programming of chip in embedded systems. Its software is used by over 14 000 companies to develop products based on 8-, 16- and 32-bit chip, mainly in industrial automation, medical equipment, consumer electronics, telecommunications and automotive industries”We have the most complete software for programming of chip in embedded systems. A growing

ÅF recruits Björn Östlund to support sustained high growth in Infrastructure

Mats Påhlsson, President,  Infrastructure Division   +46 (0)70-534 64 00Viktor Svensson, Director, Corporate Information +46 (0)70-657 20 26 ÅF has recruited Björn Östlund, Manager for the Traffic Business Area at theSwedish Transport Administration, to lead the work of the InfrastructurePlanning business area in ÅF's Infrastructure Division. This marks yet anotherstep in ÅF's strategic plan for expansion within infrastructure consultingservices. Björn will lead and expand the work of an Infrastructure Planning teamof more than 450 consultants. (In all, the Infrastructure

Interim financial report, first quarter 2011

Summary: Vestas generated first-quarter revenue of EUR 1,060m, an increase of 25 per cent relative to the first quarter of 2010, and as announced realised a loss. The EBIT margin fell from (4.6) per cent to (6.5) per cent. The development confirms that revenue and earnings may show major quarter-on-quarter fluctuations depending on the capacity utilisation and the type of projects handed over. The first half year of 2011 is expected to break even against an EBIT loss of EUR 219m during the first half year of 2010. The free cash flow was improved compared to the first quarter of 2010 by

PA Resources’ Production report for April, 2011

PA Resources’ average production of oil per day* (barrels per day) Year to Date 2011 April 2011West Africa 5,900 5,000North Africa 3,500 3,600Group Total 9,400 8,600 * Production based on Working Interest, which is PA Resources’ share of the total gross production on the oil fields before deduction of royalties and other taxes. Data for April is preliminary and includes average production 1 - 26 April, 2011. · West Africa: Production at the Azurite Field in the Republic of Congo in April has continued to be

Reminder: Invitation to presentation of Orkla's Q1-11 results

Orkla will report first quarter 2011 results on Thursday, 5 May 2011 at 7.00 a.m. CET. The quarterly report and the presentation materials will be available at this time at www.orkla.com.   A presentation of the first quarter results will be held at 8.00 a.m. at Vika Atrium Conference Center, Munkedamsveien 45,  in Oslo. The presentation will be held in English and may be seen live on webcast at www.orkla.com.     Orkla ASAOslo, 4 May 2011   Contact Orkla Investor Relations:Siv Merethe S. BrekkeTel: +47 2254 4455

PA Resources AB: Interim Report first quarter 2011

Summary · Total revenue for the Group during the first quarter amounted to SEK 583.2 million (410.2). · EBITDA for the quarter totalled SEK 358.8 million (207.5).  · Profit before tax for the first quarter was SEK 143.3 million (-88.5). · Earnings per share before and after dilution were SEK 0.08 (-0.27). · A five-year unsecured bond loan of NOK 900 million, with proceeds payable in April, was issued to refinance bond loans maturing in June 2011 and March 2012. · Following completion of the refinancing in April, cash and cash equivalents amounted to SEK 500.4 million.

TRADEDOUBLER AB (PUBL) INTERIM REPORT JANUARY-MARCH 2011

Strong start of 2011 (Numerical data in brackets refers to the corresponding period in 2010 unless otherwise stated).   ·          Net sales increased by 6% to SEK 749.4 M (709.2). Adjusted for changes in exchange rates the rise was 16%. ·          Gross profit increased by 2% to SEK 166.7 M (163.9). Adjusted for changes in exchange rates, the rise was 11%. ·          Operating profit (EBIT) increased by 109% to SEK 33.6 M (16.0). Adjusted for changes in exchange rates, the increase was 231%. ·          Network developed strongly and increased the operating profit by 141%

New mitochondrial control mechanism discovered

Scientists have discovered a new component of mitochondria that plays a key part in their function. The discovery, which is presented in the journal Cell Metabolism, is of potential significance to our understanding of both inherited and age-related diseases.Mitochondria are normally called the cell’s power plants since they convert the energy in our food into a form that the body can use. To work properly, the mitochondria have to form new proteins, which they do in their ribosomes. A group of researchers at Karolinska Institutet 

Interim Report January – March 2011

· Comparable sales1) for the first quarter increased by 1 percent to 2,646 MSEK (2,608). In local currencies, comparable sales1) for the first quarter increased by 6 percent. Sales for the first quarter of 2010 including businesses transferred to STG amounted to 3,282 MSEK · Comparable operating profit2) for the first quarter increased by 11 percent to 729 MSEK (655). In local currencies, comparable operating profit2) for the first quarter increased by 17 percent · Operating profit including businesses transferred to STG, share of net profit from STG and larger one time items3) for

Meda AB (publ) – Interim report, January-March 2011

· Group sales reached SEK 2,944 million (2,943). At a fixed currency rate, sales increased 10%. · EBITDA amounted to SEK 1,119 million (1,059), corresponding to a 38.0% margin (36.0). · Operating profit amounted to SEK 650 million (660). · Profit after tax increased to SEK 373 million (360). · Earnings per share rose to SEK 1.23 (1.19). · Cash earnings per share reached SEK 1.99 (2.07).   Highlights Acquisition of Antula complete · The acquisition of Antula announced in February 2011 was completed at the end of April. · The purchase price amounted

Sectra receives FDA clearance for MicroDose Mammography modality

First-of-its-kind technology enables women to benefit from significant reduction of radiation exposure Women in the US will now have the same opportunity as million of European women already have; to undergo mammography with significantly lower radiation dose. This is the result of FDA’s (Food and Drug Administration) clearance of the Swedish IT and medical technology company Sectra’s digital mammography system, Sectra MicroDose Mammography . Achieving best-in-class cancer detection 

Communique from annual general meeting of Dannemora Mineral

COMMUNIQUE FROM ANNUAL GENERAL MEETING OF DANNEMORA MINERAL   The annual general meeting of the shareholders of Dannemora Mineral (publ) was held on 3 May 2011. The meeting dealt with the following business:Allocation of earningsThe annual general meeting adopted the income statements and balance sheets of the Parent Company and the Group for 2010. The meeting also adopted the Board's proposal for allocation of profits, namely that no dividend be paid for the 2010 financial year. Discharge from liabilityThe annual general meeting discharged the Board members and the CEO from

First quarter report 2011 - Lundbeck is off to a good start in 2011 as key products maintain momentum

H. Lundbeck A/S (Lundbeck) reports first quarter revenue of DKK 4,103 milliongrowing 7% compared to the same period last year. The increase was driven bypositive development in all key products. Profit from operations was DKK 1,305million, increasing 4% and corresponding to an EBIT margin of 31.8%.* Continued solid growth in the key products Cipralex(®), Ebixa(®) and Azilect(®), growing 6%, 12% and 15% respectively. * Revenue from Xenazine(®) was DKK 208 million and increased 74%. * Sabril(®) sales increased 123% to DKK 75 million. * Operating profit before depreciation and

RAUTE CORPORATION - INTERIM REPORT JANUARY 1 - MARCH 31, 2011

RAUTE CORPORATION INTERIM REPORT 4 MAY 2011 AT 9:00 A.M.RAUTE CORPORATION - INTERIM REPORT JANUARY 1 - MARCH 31, 2011 - The Group’s net sales, EUR 14.6 million (MEUR 10.4), increased 40% on the comparison year.- Operating loss was EUR -1.4 million (MEUR -1.4). Result before taxes was EUR -1.6 million (MEUR -1.4).- Earnings per share (undiluted) were EUR -0.32 (EUR -0.24).- Order intake was EUR 29 million (MEUR 25) and the order book at the end of the reporting period increased to EUR 48 million (MEUR 37).- The outlook for financial performance remained unchanged. Net sales for

Notice of the Annual General Meeting 2011

The Annual General Meeting of BWG Homes ASA will take place on Thursday 26 May 2011 at 10:00 a.m. at Vika Atrium Conference Centre, Munkedamsveien 45 in Oslo, Nyland conference room.    Notice of the Annual General Meeting including appendices is enclosed. The notice of the Annual General Meeting is posted to the shareholders on 4 May 2011, and is also published on www.bwghomes.no.   This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

RaySearch Laboratories AB (publ) Interim Report January 1 – March 31, 2011

january 1 – march 31, 2011 · Net sales for the period totaled SEK 23.0 M (28.1) · Profit after tax was SEK 1.6 M (8.2), corresponding to earnings per share of SEK 0.05 (0.24) · Operating profit totaled SEK 2.1 M (11.2) · Cash flow was a negative SEK 3.3 M (negative: 1.8) · RaySearch established a sales organization in the US · Two new RayStation® orders received · RaySearch licensed groundbreaking technology from Princess Margaret Hospital SIGNIFICANT EVENTS AFTER THE CLOSE OF THE PERIOD · Dutch clinic placed an order for RayStation® in April ”The beginning

Read original

BJÖRN BORG AB INTERIM REPORT JANUARY – MARCH 2011

New markets begin to growFIRST QUARTER,JANUARY 1 – MARCH 31, 2011 · The Group’s net sales increased by 2 percent to SEK 151.3 million (148.4). Excluding currency effects, sales rose by 6 percent. · The gross profit margin decreased to 50.4 percent (51.6). · Operating profit amounted to SEK 28.4 million (36.0), a decrease of 21 percent. · Profit after tax amounted to SEK 20.7 million (25.8), a decrease of 20 percent. · Earnings per share decreased to SEK 0.89 (1.03).Fully diluted earnings per share amounted to SEK 0.88 (1.01). · Brand sales (excluding VAT) increased

GROWTH IN SRV'S ORDER BACKLOG REMAINED STRONG - SRV'S INTERIM REPORT 1 JANUARY - 31 MARCH 2011

SRV GROUP PLC                                              INTERIM REPORT 4 May 2011, 8.30 a.m.Reporting period 1 January–31 March 2011 in brief: · SRV’s revenue was EUR 132.6 million (EUR 93.8 million in January–March 2011), change +41.3% · Operating profit was EUR 1.0 million (EUR 1.6 million), change -35.4% · Profit before taxes was EUR 1.7 million (EUR 0.2 million · The order backlog at the close of the review period was EUR 702.2 million (EUR 530.0 million), change +32.5% · New contracts EUR 220.2 million (EUR 140.6 million), change +56.6% · The equity ratio was 33.

Notice of Extraordinary General Meeting in Orexo

The shareholders in Orexo AB (publ) are summoned an extraordinary general meeting to be held on Friday May 27, 2011 at 11:00 a.m. CET at 7A, Strandvägen 7A in Stockholm, Sweden. Participation, etcShareholders who wish to participate in the meeting must be recorded in the share register maintained by Euroclear Sweden AB on Saturday May 21, 2011, and notify Orexo of their intention to attend the meeting not later than on Monday May 23, 2011 by post to Orexo AB, P.O. Box 303, SE-751 05 Uppsala, Sweden, by telephone +46 (0) 18 780 88 00, by telefax +46 (0) 18 780 88 88, or by e-mail to

Orexo launches underwritten rights issue of MSEK 250

Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Japan or Australia.Read more about Orexo Rights Issue at:http://www.orexo.com/en/Investor-Relations/Rights-issue---Important-Information/ For further information, please contact: Anders Lundström, President and CEO of Orexo Tel: +46-18-780 88 12 E-mail: anders.lundström@orexo.com (anders.lundstr%C3%B6m@orexo.com) Håkan Åström, Chairman of the Board of Orexo Tel: +46-70-622 59 93 E-mail: hakanastrom@aol.com            About Orexo Orexo is a pharmaceutical

Interim report 1 January – 31 March 2011

Three months ended 31 March 2011 · Local currency sales increased by 7% and Euro sales increased by 10% to €396.8m (€361.9m). Excluding Oriflame's discontinued business in Iran, sales growth was 10% in local currency. · Average size of the sales force increased by 9% to 3.8m consultants and closing sales force was up by 8%. · EBITDA amounted to €53.3m (€49.3m). · Adjusted operating margin was 11.8% (11.7%) resulting in an adjusted operating profit of €46.7m (€42.2m). · Adjusted net profit amounted to €31.5m (€37.2m). · Adjusted EPS after dilution amounted to €0.55 (€0.65)

Interim report, January-March 2011

References made in this interim report relate to the Group unless otherwise stated. Figures in parentheses relate to the same period in the previous year.For the period ·  Abstral® sales continued to develop well in Europe and the product has now been approved in the US and Canada. ·  Anders Lundström appointed new CEO. ·  Positive data from the first clinical trial in the OX51 project, for treatment of acute intensive pain episodes. ·  Net revenues increased to MSEK 41.5 (36.4). ·  Royalty revenues from Abstral in Europe amounted to MSEK 14.0 (8.5). ·  The loss after

Thinking For Sale By Owner: Think again!

05.03.2011– TORONTO, ON., May 03, 2011 – How many For Sale By Owner (FSBO) properties are actually sold without real estate agents? Unfortunately the FSBO companies offering à la carte services, commission free models and flat rates don’t share this information.By creating the illusion that it’s much more cost effective to use For Sale By Owner models, are these companies really being truthful with consumers about what happens in the real estate industry? They offer cheaper rates to get your home listed on the MLS, provide you with “for sale” signs and offer some real estate related

There are no items matching the current filter
There are no more items matching the current filter
Back to top